Pfizer racks up its third cancer drug OK in 2 months, but is it enough to replace regular price hikes?
Pfizer has notched another win for the late-stage drug pipeline, scoring an accelerated FDA approval for lorlatinib, now headed for the market as Lorbrena.
The drug is an ALK/ROS1 TKI for metastatic non-small cell lung cancer — the latest in a line of these drugs — now approved as a second-line treatment for patients who have failed crizotinib and at least one other ALK inhibitor. And you can be sure that Pfizer didn’t pass on the chance of boasting about its third cancer drug OK in the past 2 months, following approvals for its PARP talazoparib and dacomitinib.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.